Trial Profile
ARI103094-Follow-Up Study for REDUCE Study Subjects [FOLLOW-UP OF 700012063]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Dutasteride (Primary)
- Indications Benign prostatic hyperplasia; Prostate cancer
- Focus Therapeutic Use
- Sponsors GSK
- 01 Mar 2013 New trial record